A long-acting oral suspension for dogs and cats with masked florfenicol nanocrystals
By coating the surface of florfenicol nanocrystals with a taste-masking shell and a sustained-release framework, and combining this with taste correction based on the differences in taste perception between dogs and cats, a long-acting oral suspension of florfenicol nanocrystals specifically for dogs and cats was prepared. This solved the problems of florfenicol's bitter taste sensitivity and poor water solubility, achieving long-acting release and high bioavailability, and improving drug administration compliance and therapeutic effect.
Patent Information
- Application Number
- CN202611531330.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-30
- Publication Date
- 2026-11-17
AI Technical Summary
When florfenicol is administered orally to dogs and cats, it can cause stress behaviors such as loss of appetite, salivation, and drooling due to its bitter taste. Furthermore, it has poor water solubility and low bioavailability, requiring frequent administration, which affects treatment compliance and efficacy.
A three-layer structure consisting of a taste-masking shell, a sustained-release framework, and a nanocrystal core is adopted. The taste-masking shell is coated with cationic methacrylate copolymer Eudragit E100, and the sustained-release framework is wrapped with insoluble quaternary ammonium methacrylate copolymer Eudragit RL100/RS100. The nanocrystals have an average particle size of 200-300 nm. Combined with a taste-differentiating agent for dogs and cats, a long-acting oral suspension of florfenicol nanocrystals with taste-masking properties specifically for dogs and cats is prepared.
It achieves complete taste masking and long-lasting release, reduces dosing frequency, improves treatment compliance and bioavailability, reduces stress response and missed doses, has good palatability, and is suitable for industrial production.
Smart Images

Figure REF-OBJ-1790738631224-000001 
Figure REF-OBJ-1790738631224-000002 
Figure REF-OBJ-1790738631224-000003
Abstract
Description
Technical Field
[0001] This invention relates to the field of veterinary drug formulation technology, specifically to a taste-masked florfenicol nanocrystal long-acting oral suspension for companion animals such as dogs and cats, and its preparation method. Background Technology
[0002] Florfenicol is a synthetic thiamphenicol-type broad-spectrum antibacterial drug. It exerts its antibacterial effect by binding to the 50S subunit of bacterial ribosomes and inhibiting protein synthesis. It exhibits strong antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, and mycoplasma, and does not have the potential aplastic anemia-causing side effect of chloramphenicol. In small animal clinical practice, florfenicol is widely used to treat bacterial diseases such as respiratory tract infections, urinary tract infections, and skin and soft tissue infections in dogs and cats. The commonly used oral dosage is 20-30 mg / kg for dogs and 20-25 mg / kg for cats, twice daily.
[0003] However, in practice, florfenicol has encountered intractable problems in its oral application. On the one hand, florfenicol has an extremely strong storage site, and dogs and cats are highly sensitive to bitter tastes, especially cats, which have more than seven functional bitter taste receptors. Their rejection reaction to bitter substances is extremely severe, and when given bitter drugs, they often exhibit stress behaviors such as refusal to eat, salivation, drooling, head shaking, struggling, biting, and even vomiting. This leads to difficulties in administration, inaccurate dosage, and decreased efficacy, and significantly affects the human-pet relationship and the owner's medication adherence. On the other hand, florfenicol has extremely poor water solubility, only about 1.2 mg / mL. After oral administration, it dissolves slowly and has low bioavailability. Moreover, conventional formulations are eliminated quickly and have a short duration of blood drug concentration, requiring multiple daily doses. As companion animals, dogs and cats not only increase the burden on their owners but also easily cause stress and missed doses, significantly affecting treatment adherence and efficacy.
[0004] To address these issues, several methods have emerged in the existing technology, which can be broadly categorized as follows: (1) Using gastric-soluble polymer materials, such as Eudragit E100, to make taste-masked granules or microcapsules through melt extrusion or granulation processes, such as CN102526007A. This type of scheme utilizes the property that E100 is insoluble in saliva but soluble in gastric juice. However, the product is a solid granule or microcapsule. The drug is released rapidly in the stomach and has no long-lasting effect. It still needs to be administered multiple times a day. (2) Dry suspensions are made by using simple flavoring methods such as sucrose and flavoring, such as CN103520111A. However, relying solely on sweeteners and flavorings to mask the bitterness lacks a physical masking barrier, and the bitterness is not completely masked. (3) Florfenicol nanocrystal technology, such as CN115337269A, is used to prepare florfenicol into nanocrystals through wet media grinding, nanoemulsion or spray drying, which improves the dissolution rate and bioavailability. However, nanocrystals are characterized by rapid dissolution and do not have sustained release and long-lasting effects. (4) Existing long-acting / sustaining formulations of florfenicol, such as florfenicol sustained-release microcapsules of Zhengdian Bio, can be made into microcapsules, granules or micro pellets by processes such as microencapsulation, spray drying and spray condensation. However, most of the current products are for poultry and livestock, such as pigs, chickens, ducks and geese, and are solid dosage forms. They do not take into account the liquid oral administration needs of dogs and cats, nor do they take into account the taste needs of dogs and cats.
[0005] Meanwhile, existing research shows that dogs can perceive sweetness and prefer sweet and meaty flavors, while cats, lacking functional sweet taste receptors, cannot perceive sweetness but have a strong preference for umami and meaty flavors, and are particularly sensitive to bitterness. This difference in taste perception between species necessitates differentiated design of taste-masking and palatability systems for dogs and cats. Summary of the Invention
[0006] To address the shortcomings of existing technologies, this invention proposes a long-acting oral suspension for dogs and cats with masked florfenicol nanocrystals and its preparation method.
[0007] The technical problem to be solved by the present invention is achieved through the following technical solution: A long-acting oral suspension of florfenicol nanocrystals for dogs and cats, by weight, is composed of the following components: 10-25 parts florfenicol, 5-15 parts taste-masking shell material, 5-15 parts sustained-release matrix material, 2-5 parts steric stabilizer, 0.3-1 part charge regulator, 1-3 parts suspending agent, 0.5-4 parts flavoring agent, appropriate amount of pH buffer, 0.05-0.2 parts preservative, and purified water to 100 parts, wherein the amount of pH buffer is sufficient to adjust the pH of the oral suspension to 5.5-6.5.
[0008] The flavor-masking shell material is a cationic methacrylate copolymer Eudragit E100 (butyl methacrylate, dimethylaminoethyl methacrylate and methyl methacrylate copolymerized in a mass ratio of 1:2:1), which is coated on the surface of slow-release nanocrystalline particles to form a flavor-masking shell by in-situ precipitation through pH control.
[0009] The sustained-release framework material is a mixture of insoluble nitrogen-permeable quaternary ammonium methacrylate copolymer Eudragit RL100 (quaternary ammonium molar content 10%) and Eudragit RS100 (quaternary ammonium molar content 5%) in a mass ratio of (1-2):(2-1), which is coated on the surface of florfenicol nanocrystals to form a sustained-release framework layer.
[0010] The pH value of the oral suspension is 5.5-6.5.
[0011] The space stabilizer is one or a combination of two of poloxamer 188, HPMC-E5, or PVP K30; the charge regulator is one of sodium dodecyl sulfate, sodium docusate, or sodium cholate; the suspending agent is microcrystalline cellulose-carboxymethyl cellulose sodium (Avicel) A composite suspension system composed of RC-591 and xanthan gum at a mass ratio of (2-4):1; the flavoring agent includes one or more of sweeteners, umami agents, flavoring agents, and amino acids, wherein the sweetener is one of sucralose, aspartame, or sodium saccharin; the umami agent is one or more of monosodium glutamate, yeast extract, or disodium 5'-inosinate; the umami agent is a meat flavoring agent and / or a fish flavoring agent; the meat flavoring agent is chicken flavoring or beef flavoring; the fish flavoring agent is fish flavoring or tuna flavoring; and the amino acid is glycine and / or taurine. When used for dogs, the flavoring agent uses sweeteners, meat flavoring agents, and amino acids; when used for cats, the flavoring agent does not include sweeteners and uses umami agents, fish flavoring agents, and taurine. The pH buffer is a citric acid-sodium citrate buffer system; and the preservative is sodium benzoate or potassium sorbate.
[0012] The preparation method of the oral suspension based on the above-mentioned components includes the following steps: Preparation of S1 flavor-masking coating solution: Dissolve Eudragit E100 in a citric acid aqueous solution with a pH of 2.5-3.5 and stir until completely dissolved to obtain the flavor-masking coating solution; Preparation of S2 sustained-release nanocrystals: A steric stabilizer and charge modifier were dissolved in purified water by stirring. Florfenicol active pharmaceutical ingredient was added and dispersed at high speed to form a coarse suspension. This suspension was then transferred to a wet media mill, and 0.3-0.5 mm zirconia grinding beads were added, with a filling rate of 60%-70%. The mixture was circulated and milled at 1500-3000 r / min for 60-120 min, with the temperature controlled not exceeding 25℃. During milling, an organic solution of Eudragit RL100 / RS100 was slowly added dropwise, allowing the sustained-release framework material to be deposited in situ on the surface of the florfenicol nanocrystals to form a sustained-release framework layer. After milling, the organic solvent was removed under reduced pressure, and the grinding beads were sieved to obtain a sustained-release nanocrystal suspension with an average nanocrystal size of 200-300 nm and a PDI ≤ 0.25. S3 In-situ pH-responsive precipitation coating: Under stirring, the flavor-masking coating solution of S1 is slowly added to the sustained-release nanocrystal suspension of S2. At the same time, the pH value of the system is adjusted to 5.5-6.5 with sodium citrate solution, so that Eudragit E100 precipitates and deposits in situ on the surface of the sustained-release nanocrystal particles due to the sudden drop in solubility, forming a dense flavor-masking shell, and thus obtaining a flavor-masking sustained-release nanocrystal suspension. Preparation of S4 suspension: Add the prescribed amount of suspending agent, flavoring agent, preservative and pH buffer to the S2 suspension, homogenize and disperse, adjust the pH to 5.5-6.5, add water to make up the volume, and the finished oral suspension is obtained.
[0013] In this invention, the organic solvent used in S2 is dichloromethane or ethyl acetate, and the organic solution of the slow-release skeleton material is a solution of Eudragit RL100 and RS100 dissolved in dichloromethane or ethyl acetate.
[0014] This invention achieves the dual functions of masking taste and long-lasting effect through a three-layer structure consisting of a taste-masking shell, a buffer framework layer, and a nanocrystalline core. The taste-masking layer uses Eudragit E100, a cationic methacrylic acid copolymer, as the outer shell. It exhibits solubility characteristics: soluble at pH < 5, insoluble but swellable at pH > 5. After in-situ precipitation via pH adjustment in step S3, E100 forms a dense polymer shell on the outermost layer of the microcrystals via molecular deposition. In the oral cavity of dogs and cats, the saliva pH is 6.8-7.4, within the insoluble region of E100. The taste-masking shell remains intact, physically preventing florfenicol from contacting the bitter taste receptors on the taste buds. The drug is almost completely insoluble in the oral cavity, achieving thorough taste masking. The long-acting sustained-release layer uses Eudragit RL100 / RS100, an insoluble nitrogen-permeable quaternary ammonium methacrylate copolymer, as the inner sustained-release framework. It is insoluble in water and digestive juices, but can swell and form permeable microporous channels, and its release behavior is unaffected by gastrointestinal pH. After ingestion, the E100 taste-masking shell dissolves in the stomach, exposing the sustained-release framework layer. The drug is slowly released through the framework's microporous channels, with a cumulative release rate of only 20%-35% over 2 hours, without burst release. Subsequent release continues throughout the gastric and intestinal tract, with a cumulative release rate of ≥80% over 24 hours. This reduces the dosing frequency in dogs and cats from multiple times daily to once daily, minimizing dosing stress and missed doses. Florfenicol is encapsulated in a cyclic framework in the form of nanocrystals (average particle size 200-300 nm). The high specific surface area and high dissolution rate of the nanocrystals overcome the inherent contradiction of insufficient release of poorly soluble drugs in traditional sustained-release formulations. After the drug is released from the sustained-release framework, it dissolves rapidly in the form of nanocrystals and is fully absorbed, thus achieving long-lasting effect while ensuring high bioavailability. The drug release rate is adjustable. Eudragit RL100 has a high quaternary ammonium content, strong skeleton permeability, and fast release. Eudragit RS100 has a low quaternary ammonium content, weak permeability, and slow release. The two are compounded in a mass ratio of (1-2):(2-1). By adjusting the quaternary ammonium ratio, the release rate can be precisely controlled, achieving individualized long-acting design for different diseases in dogs and cats.
[0015] This invention also addresses the physiological differences in taste perception between dogs and cats by implementing differentiated flavoring. Dogs can perceive sweetness and prefer meat flavors, so the canine formula uses a combination of sweeteners, meat flavoring agents, and umami amino acids. Cats lack functional sweet taste receptors and cannot perceive sweetness, but they prefer umami and meat flavors. Therefore, the cat formula abandons sweeteners and instead uses a combination of umami agents, fish flavoring agents, and taurine. Taurine is an essential amino acid for cats, which can supplement nutrition and synergistically improve palatability.
[0016] Compared with the prior art, the present invention has the following advantages: (1) The present invention achieves thorough taste masking and long-term release through a three-layer structure of taste-masking shell, sustained-release skeleton and nanocrystal core, overcoming the dual limitations of existing taste-masking preparations that have no long-term effect in gastric sustained release and existing nanocrystal preparations that are quick-dissolving and have no taste masking. (2) The present invention uses nanocrystal technology to achieve long-lasting effect while ensuring high dissolution and high bioavailability, thereby reducing the dosage and reducing drug resistance and adverse reactions; (3) The present invention achieves long-acting release, reducing the frequency of administration to dogs and cats from multiple times a day to once a day, significantly reducing administration stress, burden on owners and missed doses, and improving treatment compliance; (4) The present invention designs a differentiated taste correction system based on the physiological differences in taste between dogs and cats, which significantly improves the acceptance of companion animals to eat independently and their compliance with drug administration. (5) This invention is a ready-to-use oral suspension that can be administered directly by liquid or mixed with a small amount of food. The dosage is flexible and easy to use. The composite suspension system used has a high sedimentation volume ratio, does not clump when left to stand, and disperses evenly when shaken, with good stability. (6) The preparation process of this invention is simple. A multi-layer structure is constructed through a continuous in-situ assembly process, without the need for complex equipment such as melt extrusion and fluidized bed coating, making it suitable for industrial production. Attached Figure Description
[0017] Figure 1 This is a particle size distribution diagram of the florfenicol flavor-masked sustained-release nanocrystals of the present invention; Figure 2 This is a curve comparing the cumulative release rate of the formulation of the present invention in vitro under different pH media (artificial saliva, artificial gastric juice, artificial intestinal juice, and 24-hour long-acting release). Figure 3 This is a plasma florfenicol concentration-time curve in dogs after oral administration of the formulation of this invention. Detailed Implementation
[0018] The present invention will be further described below with reference to specific preferred embodiments, but this does not limit the scope of protection of the present invention.
[0019] Unless otherwise specified, the raw materials, equipment and testing standards used in the embodiments of this invention are all commercially available products, conventional industrial equipment and national / industry general standards in the field.
[0020] (a) Sample preparation Example 1
[0021] This embodiment is a preferred formulation of a long-acting, odor-masking, nanocrystalline oral suspension for dogs.
[0022] The prescription, by weight, is as follows: Florfenicol 15 parts, Eudragit E100 10 parts, Eudragit RL100 5 parts, Eudragit RS100 5 parts, Poloxamer 188 3 parts, Sodium lauryl sulfate 0.5 parts, Avicel RC-591 1.5 parts, Xanthan gum 0.5 parts, Sucralose 0.1 parts, Monosodium glutamate 0.8 parts, Glycine 0.5 parts, Chicken flavoring 0.8 parts, Sodium benzoate 0.1 parts, Citric acid 1 part, Sodium citrate 2 parts (adjust pH to 6.0), purified water to 100 parts.
[0023] Preparation process: (1) Take 100 g of Eudragit E100 and dissolve it in 300 mL of citric acid aqueous solution with pH 3.0. Stir until completely dissolved to obtain a flavor-masking coating solution; (2) Dissolve 30 g of poloxamer 188 and 5 g of sodium dodecyl sulfate in 500 mL of purified water, add 150 g of florfenicol, and disperse at 10000 r / min for 30 min to form a coarse suspension; (3) Transfer to a wet media mill, add 0.4 mm zirconia beads, fill rate 65%, and circulate and grind at 2500 r / min. During the grinding process, slowly add Eudragit RL100 50 g and RS100 50 g dissolved in 200 mL of dichloromethane solution. After the addition is completed, continue grinding until the total grinding time is 90 min. The temperature is controlled at 20±2℃. Remove dichloromethane under reduced pressure and separate the grinding beads through a 200 mesh sieve to obtain a slow-release nanocrystalline suspension. (4) While stirring, slowly add the flavor-masking coating solution to the sustained-release nanocrystal suspension, and at the same time adjust the pH to 6.0 with sodium citrate solution. Continue stirring for 30 min to allow E100 to precipitate and coat in situ, thus obtaining the flavor-masking sustained-release nanocrystal suspension. (5) Add 15 g of Avical RC-591, 5 g of xanthan gum, 1 g of sucralose, 8 g of monosodium glutamate, 5 g of glycine, 8 g of chicken flavoring, 1 g of sodium benzoate, 10 g of citric acid, and 20 g of sodium citrate. Disperse the mixture homogeneously. If necessary, adjust the pH to 6.0 with citric acid-sodium citrate. Add water to make up to 1000 mL to obtain the finished product.
[0024] Example 2
[0025] This embodiment is a preferred formulation of a cat-specific, long-acting, odor-masking, nanocrystalline oral suspension.
[0026] The prescription, by weight, is as follows: Florfenicol 20 parts, Eudragit E100 12 parts, Eudragit RL100 6 parts, Eudragit RS100 8 parts, Poloxamer 188 4 parts, Sodium lauryl sulfate 0.6 parts, Avicel RC-591 1.5 parts, Xanthan gum 0.5 parts, Monosodium glutamate 1.0 part, Yeast extract 0.8 parts, Tuna flavor 0.8 parts, Taurine 0.8 parts, Sodium benzoate 0.1 parts, Citric acid 1 part, Sodium citrate 2 parts (adjust pH to 6.2), purified water to 100 parts.
[0027] The preparation process is the same as in Example 1, with a grinding time of 100 min, and the finished product pH is 6.2. The cat formula does not contain sweeteners.
[0028] Example 3
[0029] This embodiment is another solution for a long-acting, odor-masking, nanocrystalline oral suspension for dogs.
[0030] The prescription, by weight, is as follows: Florfenicol 10 parts, Eudragit E100 8 parts, Eudragit RL100 4 parts, Eudragit RS100 4 parts, HPMC-E5 3 parts, Sodium docusate 0.4 parts, Avicel RC-591 1.0 part, Xanthan gum 0.5 parts, Sucralose 0.08 parts, Glycine 0.5 parts, Beef flavoring 0.6 parts, Sodium benzoate 0.08 parts, Citric acid 1 part, Sodium citrate 2 parts (adjust pH to 5.8), purified water to 100 parts.
[0031] The preparation process was the same as in Example 1, the grinding time was 100 min, and the pH of the finished product was 5.8.
[0032] Comparative Example 1 The formulation and preparation process are the same as in Example 1, but the Eudragit RL100 / RS100 sustained-release matrix material is removed; the remaining components and process remain unchanged. This is used to verify the key role of the sustained-release matrix in long-acting release.
[0033] Comparative Example 2 The formulation and preparation process are the same as in Example 1, but the Eudragit E100 taste-masking shell material is removed; the remaining components and process remain unchanged. This is used to verify the key role of the taste-masking shell in the taste-masking function.
[0034] Comparative Example 3 The formulation and preparation process are the same as in Example 1, but Eudragit E100 and Eudragit RL100 / RS100 are removed, while the remaining components and processes remain unchanged.
[0035] Comparative Example 4 The formulation and preparation process are the same as in Example 2, but 0.1 parts of sucralose are added to verify the necessity of the differentiated design.
[0036] Comparative Example 5 The formulation and preparation process were the same as in Example 1, but poloxamer 188 and sodium dodecyl sulfate were removed to verify the effect of stabilizers on the dispersion state of nanocrystals and on taste masking and sustained-release properties.
[0037] (ii) Performance testing 2.1 Measurement of nanocrystal size, PDI and Zeta potential Test criteria: The average particle size and polydispersity index (PDI) of nanocrystals were determined by dynamic light scattering (DLS), referring to the "Determination of Particle Size and Particle Size Distribution" in the 2020 edition of the Chinese Veterinary Pharmacopoeia; Zeta potential was determined according to ISO 13099-1:2012.
[0038] The particle size, PDI and Zeta potential of each sample were measured after preparation and after being placed at room temperature for 3 months. The results are shown in Table 1.
[0039] Table 1 shows the detection results of particle size, PDI, and Zeta potential for each sample (n=3).
[0040] The results showed that the nanocrystals in Examples 1-3 had a particle size of 200-300 nm and a PDI ≤ 0.25. Furthermore, the E100 cation shell imparted a positive surface potential, resulting in a stable suspension system. In contrast, Example 5, lacking a stabilizer, exhibited severe particle agglomeration and a significantly increased particle size after grinding, indicating that steric stabilizers and charge modifiers are indispensable for maintaining the dispersion of the nanocrystals.
[0041] 2.2 Examination of taste masking and long-term release Test criteria: The method of "Dissolution and Release Determination" (Method II, Paddle Method) of the 2020 edition of the Chinese Veterinary Pharmacopoeia was used; the artificial gastric fluid (pH 1.2) was prepared according to the "Test Solution" section of the 2020 edition of the Chinese Veterinary Pharmacopoeia, and the artificial saliva (pH 6.8) was prepared using phosphate buffer solution.
[0042] Each formulation was first placed in artificial saliva at pH 6.8 (37℃) for 2 min to simulate the oral environment and assess taste masking. Then, it was transferred to artificial gastric juice at pH 1.2 (37℃) for 2 h to simulate the gastric environment. Subsequently, it was transferred to artificial intestinal juice at pH 6.8 (37℃) for further release until 24 h. Samples were taken at 2 h, 8 h, and 24 h to determine the cumulative release rate. The results are shown in Table 2.
[0043] Table 2 shows the cumulative in vitro release rate (%, n=3, x±s) for each sample.
[0044] The results showed that the cumulative release rate of Examples 1-3 in artificial saliva was ≤5% at 2 min, achieving complete taste masking; the cumulative release rate in artificial gastric juice was only 25%-30% at 2 h, with no burst release, and the cumulative release rate at 24 h was ≥90%, exhibiting sustained long-acting release characteristics. Comparative Example 1 (without sustained-release matrix) released 84.6% in the stomach at 2 h, essentially a complete burst release, verifying that the sustained-release matrix is key to long-acting release; Comparative Example 2 (without taste-masking shell) released as high as 27.8% in artificial saliva at 2 min, failing to mask the taste, but its long-acting release was comparable to the examples, verifying that the E100 shell is key to taste masking and does not affect long-acting drug release; Comparative Example 3 had neither taste masking nor long-acting effect; Comparative Example 5 had increased oral leakage rate and decreased sustained-release performance due to nanocrystal aggregation and incomplete coating.
[0045] 2.3 Evaluation of bitterness value by electronic tongue The bitterness intensity of each sample was determined using the Alpha MOS ASTREE electronic tongue system. Before measurement, the bitterness sensor of the electronic tongue was calibrated with quinine hydrochloride solution. With a bitterness value of 1.0 mg / mL florfenicol aqueous solution (25℃) as 100, each formulation sample was diluted with florfenicol to 1.0 mg / mL and measured under the same conditions. The results are shown in Table 3.
[0046] Table 3 shows the bitterness intensity values of each sample on the electronic tongue (n=3).
[0047] The results showed that the bitterness value of the electronic tongue in Examples 1-3 decreased by more than 86% compared with the raw drug, and the taste masking effect was significant. Comparative Examples 2 and 3 had no taste masking shell and the bitterness value was still high, proving that the E100 taste masking shell plays a decisive role in taste masking.
[0048] 2.4 Palatability test for canines and cats to consume food independently Twelve healthy adult Beagles and twelve healthy adult shorthaired domestic cats were randomly assigned to two groups. Beagles are an internationally recognized standard experimental dog breed with stable eating behavior and are widely used in the evaluation of veterinary drug palatability. The taste receptor types of dogs and cats are common at the species level and do not vary from breed to breed. Therefore, the palatability results of the above single breeds have general reference significance for the same species.
[0049] Each formulation was mixed into a small amount of regular diet at the same florfenicol dose (20 mg / kg), and the spontaneous feeding behavior was recorded within 15 minutes. The feeding acceptance rate was calculated, and the results are shown in Table 4.
[0050] Table 4 shows the acceptance rate (%) of dogs and cats to self-feeding.
[0051] The results showed that in Example 1 (for dogs), the spontaneous acceptance rate of dogs reached 91.7% (only 1 out of 12 dogs had low acceptance), and in Example 2 (for cats), the acceptance rate of cats reached 83.3% (only 2 out of 12 cats had low acceptance), significantly higher than the control group without taste masking. In Control Group 4, after adding a sweetener to the cat formula, the cat acceptance rate was 25.0%, not significantly different from Example 2 (83.3%) with the sweetener. This indicates that the sweetener did not improve palatability in cats, confirming the species characteristic that cats lack functional sweet taste receptors and cannot perceive sweetness. Therefore, the cat formula does not require the addition of sweeteners, verifying the necessity of the differentiated taste-enhancing system of this invention.
[0052] 2.5 Content, related substances and sedimentation volume ratio Testing basis: Refer to the content determination and related substance test method of florfenicol under Part I of the Chinese Veterinary Pharmacopoeia 2020 edition; sedimentation volume ratio refers to the general rules for "oral suspension" preparations in the Chinese Veterinary Pharmacopoeia 2020 edition (the sedimentation volume ratio should not be less than 0.90).
[0053] The florfenicol content in Examples 1-3 was determined to be 99.0%, 98.6%, and 99.3%, respectively, with the largest single impurity ≤0.2% and the total impurities ≤0.8%. After reconstitution, the sedimentation volume ratio was ≥0.95, and the mixture was completely redispersed after standing for 24 hours and shaking less than 10 times, without any agglomeration. In Comparative Example 5, due to nanocrystal agglomeration, the sedimentation volume ratio dropped to 0.71, making redispersibility difficult.
[0054] 2.6 Accelerated Stability Assessment Testing basis: Technical Guidelines for Stability Studies of Veterinary Chemical Drugs.
[0055] Both Example 1 and Comparative Example 5 were subjected to accelerated storage at 40±2℃ and 75±5% relative humidity for 6 months to examine key quality indicators. The results showed that after 6 months of accelerated storage, the particle size, taste masking and long-lasting release performance, content, and impurities (i.e., sedimentation volume ratio) of Example 1 all met the limit requirements, and the taste masking shell and sustained-release skeleton remained intact. In contrast, due to the continuous aggregation of nanocrystals and damage to the coating, the oral release rate of Comparative Example 5 continued to increase, and the sustained-release performance gradually decreased.
[0056] 2.7 Pharmacokinetic Study in Dogs Detection criteria: The concentration of florfenicol in canine plasma was determined using a validated liquid chromatography-tandem mass spectrometry (LC-MS / MS) method; pharmacokinetic parameters were calculated using a non-compartmental model in accordance with the "Technical Guidelines for Non-Clinical Pharmacokinetic Studies of Veterinary Chemical Drugs".
[0057] Twelve healthy adult beagles were randomly divided into two groups. The first group received the formulation of Example 1 via gavage, while the second group received the formulation of Comparative Example 1 (a taste-masked immediate-release formulation without a sustained-release matrix). The dosage for both groups was 20 mg / kg. Blood samples were collected from multiple sites after administration to determine plasma drug concentrations. The main pharmacokinetic parameters are shown in Table 5.
[0058] Table 5 shows the main pharmacokinetic parameters of canine plasma (n=6, x±s).
[0059] The results showed that, compared with Comparative Example 1 (immediate release), the peak time T of Example 1 was significantly shorter. max The terminal elimination half-life t was delayed from 1.6 h to 5.4 h. 1 / 2 The mean residence time (MRT) was extended from 8.0 h to 15.8 h, and the effective plasma concentration maintenance time was extended from approximately 12 h to over 24 h. The area under the curve (AUC) increased by 20.0%, achieving the pharmacokinetic basis for once-daily dosing while avoiding the problems of excessively high peak concentrations and rapid elimination associated with immediate-release formulations. This verifies the technical effect of the three-layer structure of the present invention—a taste-masking shell, a sustained-release framework, and a nanocrystalline core—in achieving both thorough taste masking and long-lasting release with high bioavailability.
Claims
1. A long-acting oral suspension of florfenicol nanocrystals specifically for dogs and cats, characterized in that, It is made from the following components in parts by weight: The oral suspension contains 10-25 parts florfenicol, 5-15 parts taste-masking shell material, 5-15 parts sustained-release matrix material, 2-5 parts steric stabilizer, 0.3-1 part charge regulator, 1-3 parts suspending agent, 0.5-4 parts flavoring agent, appropriate amount of pH buffer, 0.05-0.2 parts preservative, and purified water to 100 parts, wherein the amount of pH buffer is used to adjust the pH of the oral suspension to 5.5-6.
5. The taste-masking shell material is a cationic methacrylic acid copolymer, which is coated on the surface of the sustained-release nanocrystal particles to form a taste-masking shell by in-situ precipitation through pH control; the sustained-release skeleton material is an insoluble nitrogen-permeable quaternary ammonium methacrylic acid copolymer, which is coated on the surface of florfenicol nanocrystals to form a sustained-release skeleton layer; the pH value of the oral suspension is 5.5-6.
5.
2. The oral suspension according to claim 1, characterized in that, The cationic methacrylic acid copolymer is Eudragit E100, obtained by copolymerizing butyl methacrylate, dimethylaminoethyl methacrylate and methyl methacrylate in a mass ratio of 1:2:1; the sustained-release skeleton material is Eudragit RL100 and Eudragit RS100 in a mass ratio of (1-2):(2-1), wherein the quaternary ammonium molar content of Eudragit RL100 is 10% and the quaternary ammonium molar content of Eudragit RS100 is 5%.
3. The oral suspension according to claim 1, characterized in that, The space stabilizer is one or a combination of two of poloxamer 188, HPMC-E5, or PVP K30; the charge regulator is one of sodium dodecyl sulfate, sodium docusate, or sodium cholate; and the suspending agent is a composite suspending system composed of Avicel RC-591 and xanthan gum in a mass ratio of (2-4):
1.
4. The oral suspension according to claim 1, characterized in that, The flavoring agent includes one or more of sweeteners, umami agents, flavoring agents, and amino acids. The sweetener is one of sucralose, aspartame, or sodium saccharin. The umami agent is one or more of monosodium glutamate, yeast extract, or disodium 5'-inosinate. The umami agent is a meat flavoring agent and / or a fish flavoring agent. The meat flavoring agent is chicken flavoring or beef flavoring. The fish flavoring agent is fish flavoring or tuna flavoring. The amino acid is glycine and / or taurine.
5. The oral suspension according to claim 4, characterized in that: When used in dogs, the flavoring agent comprises sweeteners, meat flavoring agents, and amino acids; when used in cats, the flavoring agent does not include sweeteners and comprises umami flavoring agents, fish flavoring agents, and taurine.
6. The oral suspension according to claim 1, characterized in that, The pH buffer is a citric acid-sodium citrate buffer system; the preservative is sodium benzoate or potassium sorbate.
7. A method for preparing a long-acting oral suspension of florfenicol nanocrystals for dogs and cats as described in any one of claims 1-6, characterized in that, Includes the following steps: Preparation of S1 flavor-masking coating solution: Dissolve Eudragit E100 in a citric acid aqueous solution with a pH of 2.5-3.5 and stir until completely dissolved to obtain the flavor-masking coating solution; Preparation of S2 sustained-release nanocrystals: The space stabilizer and charge regulator were added to purified water and stirred to dissolve. Florfenicol active pharmaceutical ingredient was added and dispersed at high speed to form a coarse suspension. The suspension was then transferred to a wet media mill and zirconium oxide grinding beads were added. During the milling process, an organic solution of the sustained-release framework material was slowly added dropwise, so that the sustained-release framework material was deposited in situ on the surface of the florfenicol nanocrystals to form a sustained-release framework layer. After milling, the organic solvent was removed by depressurization and the grinding beads were separated by sieving to obtain a sustained-release nanocrystal suspension. S3 In-situ pH-responsive precipitation coating: Under stirring, the flavor-masking coating solution of S1 is slowly added to the sustained-release nanocrystal suspension of S2. At the same time, the pH value of the system is adjusted to 5.5-6.5 with sodium citrate solution, so that Eudragit E100 precipitates and deposits in situ on the surface of the sustained-release nanocrystal particles due to the sudden drop in solubility, forming a dense flavor-masking shell, and thus obtaining a flavor-masking sustained-release nanocrystal suspension. Preparation of S4 suspension: Add the prescribed amount of suspending agent, flavoring agent, preservative and pH buffer to the S2 suspension, homogenize and disperse, adjust the pH to 5.5-6.5, add water to make up the volume, and the finished oral suspension is obtained.
8. The preparation method according to claim 7, characterized in that, The zirconium oxide grinding beads described in S2 have a particle size of 0.3-0.5 mm, a filling rate of 60%-70%, a grinding speed of 1500-3000 r / min, a grinding time of 60-120 min, and the grinding process temperature is controlled to not exceed 25℃.
9. The method according to claim 7, characterized in that, The organic solvent used in S2 is dichloromethane or ethyl acetate, and the organic solution of the slow-release framework material is a solution of Eudragit RL100 and RS100 dissolved in dichloromethane or ethyl acetate.
Citation Information
Patent Citations
Florfenicol taste masking preparation and preparation method for same
CN102526007A
Florfenicol dry suspension, and preparation method and application thereof
CN103520111A
Florfenicol mixed-drinking nanocrystalline solid dispersion preparation as well as preparation method and application of florfenicol mixed-drinking nanocrystalline solid dispersion preparation
CN115337269A
